Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3414 - First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors


10 Oct 2016


Poster display


Eric Angevin


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


E. Angevin1, K. Kelly2, R. Heist3, D. Morgensztern4, C. Weekes5, T.M. Bauer6, R.K. Ramanathan7, J. Nemunaitis8, X. Fan9, O. Olyaie9, A. Parikh9, E. Reilly10, D. Afar9, L. Naumovski9, J. Strickler11

Author affiliations

  • 1 Early Drug Development Department, Gustave Roussy, 94800 - VILLEJUIF CEDEX/FR
  • 2 Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento/US
  • 3 Children Cancer Center, Massachusetts General Hospital, Boston/US
  • 4 Oncology, Washington University School of Medicine, St. Louis/US
  • 5 Department Of Medicine, University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora/US
  • 6 Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville/US
  • 7 Hematology/oncology, Mayo Clinic Cancer Center, 85259 - Phoenix/US
  • 8 Oncology, Mary Crowley Cancer Research Center, Dallas/US
  • 9 Biotherapeutics, AbbVie, Redwood City/US
  • 10 Oncology, AbbVie, Inc., North Chicago/US
  • 11 Department Of Medicine, Duke University Medical Center, Durham/US


Abstract 3414


The c-Met receptor is overexpressed in multiple tumors. ABBV-399 is a first-in-class ADC composed of ABT-700, a previously described anti–c-Met antibody, conjugated to monomethyl auristatin E (a microtubule inhibitor). Preclinical data support ADC ABBV-399 as a unique strategy to deliver a potent cytotoxin directly to c-Met+ tumor cells (∼30-50% of tumors overexpress c-Met).


In a 3 + 3 dose-escalation design, ABBV-399 was administered at doses ranging from 0.15 to 3.3 mg/kg once every 21 days to pts with metastatic solid tumors (NCT02099058). ABBV-399 was then studied in a dose-expansion cohort in pts with c-Met+ (immunohistochemistry [IHC] H-score ≥150) non-small cell lung cancer (NSCLC). Overexpression of c-Met was assessed by an IHC assay utilizing the SP44 antibody (Ventana; Tucson, AZ, USA).


As of March 31, 2016, 48 pts received at least 1 dose of ABBV-399. Approximately dose-proportional increases of area under the curve for ABBV-399 and total antibody were observed after single-dose administration. Half-lives for ABBV-399 and total antibody were approximately 2 to 4 days. Dose-limiting toxicity of febrile neutropenia occurred in 1 pt at 3 mg/kg and 1 pt (with septic shock) at 3.3 mg/kg. A dose of 2.7 mg/kg was chosen for dose expansion based primarily on safety and tolerability. There were no treatment-related deaths. Treatment-related adverse events occurring in ≥10% of pts (including all dose levels and all grades) were fatigue (22.9%), nausea (20.8%), neuropathy (14.6%), decreased appetite (12.5%), vomiting (12.5%), and hypoalbuminemia (10.4%). Three of 16 (18.8%) ABBV-399–treated c-Met+ NSCLC pts had a partial response with duration of response 1 + , 3, and 4.5 mo. At week 12, 6 of 16 (37.5%) had disease control. There were no responses among pts with c-Met–negative tumors.


ABBV-399 is well tolerated at a dose of 2.7 mg/kg every 21 days and has demonstrated promising antitumor activity in pts with cMet+ NSCLC. Assessment of antitumor activity and safety of ABBV-399 in c-Met+ pts will continue as monotherapy and in combination with standard of care.

Clinical trial identification


Legal entity responsible for the study

AbbVie, Inc.


AbbVie, Inc.


D. Morgensztern: Speaker: Genentech, Boehringer Ingelheim; consultant: Genentech, Celgene, Heat Biologics, Bristol-Myers Squibb. R.K. Ramanathan, J. Strickler: Research funding from AbbVie. X. Fan, O. Olyaie, A. Parikh, E. Reilly, D. Afar, L. Naumovski: Employed by AbbVie and may own stock. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings